Comparative Pharmacology
Head-to-head clinical analysis: HIPPURAN I 131 versus MACROTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPURAN I 131 versus MACROTEC.
HIPPURAN I 131 vs MACROTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
Not applicable for diagnostic use.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical